Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | SLC26A6 | Q9BXS9 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5777232 | 0.85 | KDM4E (0.49) | TSHRARALDH1A1KDM4EPOLB | |
| SCHEMBL15622305 | 0.82 | AR (0.47) | KMT2AARALDH1A1KDM4EPOLB | |
| SCHEMBL5778710 | 0.81 | SMN1; SMN2 (0.52) | L3MBTL1TSHRRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29025464 | 0.80 | TSHR (0.41) | TSHRNPC1KMT2ARAB9AALDH1A1 | |
| SCHEMBL5779014 | 0.78 | PDE3B (0.49) | TSHRRAB9AJAK2JAK3SLC26A6 | |
| SCHEMBL7512080 | 0.77 | TSHR (0.50) | TSHRKMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL17619356 | 0.76 | AR (0.48) | KMT2AARALDH1A1KDM4E | |
| SCHEMBL20976756 | 0.76 | AR (0.43) | KMT2AARALDH1A1KDM4EPOLB | |
| SCHEMBL3356162 | 0.76 | KMT2A (0.49) | L3MBTL1TSHRKMT2AALDH1A1KDM4E | |
| SCHEMBL3582571 | 0.75 | NPC1 (0.46) | L3MBTL1TSHRNPC1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2897953-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2897953-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20170065586-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170065586-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170065586-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-9487508-B2 | SGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487508-B2 | SGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487508-B2 | SGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20150232461-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150232461-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150232461-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-08-20 | — | — | US | disclosed |
| EP-2897953-A1 | SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2015-07-29 | — | — | EP | disclosed |
| WO-2014047325-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014047325-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | WO | disclosed |
| EP-1678181-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042534-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232461-A1 | SGC STIMULATORS | GUCY1B1, GUCY1A1, PRKG1 | L3MBTL1 4842/4885TSHR 1149/4885NPC1 4278/4885 |
| US-20170065586-A1 | SGC STIMULATORS | GUCY1B1, GUCY1A1, PRKG1 | L3MBTL1 4842/4885TSHR 1149/4885NPC1 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.